All In Biotech

NDA 022007 · Viatris Specialty

Perforomist

Formoterol Fumarate · Inhalation

Last checked: Nov 20, 2026Latest source record: May 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 11, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

514

215 Phase 3, 21 recruiting

FAERS reports

4,757

3,925 serious, 538 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2020.

Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • Formoterol fumarate inhalation solution is not indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1.2 Important Limitations of Use Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see Warnings and Precautions (5.2) ]. Formoterol fumarate inhalation solution is not indicated to treat asthma. The safety and effectiveness of formoterol fumarate inhalation solution in asthma have not been established.

Mechanism: Formoterol fumarate is a long-acting, beta 2 -adrenergic receptor agonist (beta 2 -agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta 2 -receptors than at beta 1 -receptors. Although beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, there are also beta 2 -receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PERFOROMIST · FORMOTEROL FUMARATE 0.02MG/2ML · SOLUTION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Formoterol" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,333
  • asthma1,150
  • cough727
  • wheezing608
  • pneumonia530
  • drug ineffective482
  • therapeutic product effect incomplete461
  • obstructive airways disorder430
  • fatigue425
  • headache405
  • gastrooesophageal reflux disease393
  • full blood count abnormal330

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200429
200547
200666
200797
200866
200989
2010106
2011470
2012457
201380
201469
2015112
2016141
2017186
2018222
2019296
2020359
2021420
2022372
2023322
2024288
2025278
2026185

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Perforomist (Formoterol Fumarate)

2024 spending

$459K

Beneficiaries

147

529 claims

Per beneficiary

$3,123

$9.11 per unit

View as table
YearSpending
2020$10,625,078
2021$5,733,043
2022$1,945,394
2023$731,875
2024$459,128

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,013 on PubMed

Sponsor: Viatris Specialty

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.